Mark Wing

3.9k total citations
47 papers, 3.0k citations indexed

About

Mark Wing is a scholar working on Immunology, Neurology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mark Wing has authored 47 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Immunology, 14 papers in Neurology and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mark Wing's work include Neuroinflammation and Neurodegeneration Mechanisms (14 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and T-cell and B-cell Immunology (7 papers). Mark Wing is often cited by papers focused on Neuroinflammation and Neurodegeneration Mechanisms (14 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and T-cell and B-cell Immunology (7 papers). Mark Wing collaborates with scholars based in United Kingdom, United States and India. Mark Wing's co-authors include Alastair Compston, Herman Waldmann, G Hale, D. A. S. Compston, Alasdair Coles, John Zajicek, Neil Scolding, John D. Isaacs, Richard Nicholas and David Miller and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Mark Wing

47 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Wing United Kingdom 29 1.2k 929 645 514 457 47 3.0k
Carol L. Vanderlugt United States 23 2.6k 2.3× 800 0.9× 537 0.8× 409 0.8× 352 0.8× 26 3.7k
B. Cannella United States 19 1.8k 1.6× 684 0.7× 635 1.0× 207 0.4× 621 1.4× 28 3.0k
Anthony Slavin United States 28 1.9k 1.6× 1.1k 1.1× 986 1.5× 210 0.4× 395 0.9× 53 3.6k
Virginia L. Calder United Kingdom 37 1.0k 0.9× 465 0.5× 552 0.9× 511 1.0× 317 0.7× 108 3.8k
Dvora Teitelbaum Israel 34 2.2k 1.9× 2.0k 2.2× 684 1.1× 598 1.2× 424 0.9× 70 4.1k
Sigrid R. Ruuls Netherlands 20 1.3k 1.1× 320 0.3× 489 0.8× 204 0.4× 852 1.9× 25 2.5k
Subramaniam Sriram United States 30 1.0k 0.9× 529 0.6× 637 1.0× 181 0.4× 308 0.7× 66 2.5k
Nathan Karin Israel 35 3.3k 2.9× 794 0.9× 1.0k 1.6× 487 0.9× 405 0.9× 62 5.2k
DeRen Huang United States 31 1.5k 1.3× 492 0.5× 661 1.0× 115 0.2× 934 2.0× 49 3.5k
Masaaki Niino Japan 30 1.3k 1.1× 1.7k 1.8× 661 1.0× 138 0.3× 244 0.5× 140 3.3k

Countries citing papers authored by Mark Wing

Since Specialization
Citations

This map shows the geographic impact of Mark Wing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Wing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Wing more than expected).

Fields of papers citing papers by Mark Wing

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Wing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Wing. The network helps show where Mark Wing may publish in the future.

Co-authorship network of co-authors of Mark Wing

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Wing. A scholar is included among the top collaborators of Mark Wing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Wing. Mark Wing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Panova, Veera, Mayuri Gogoi, Noé Rodríguez‐Rodríguez, et al.. (2020). Group-2 innate lymphoid cell-dependent regulation of tissue neutrophil migration by alternatively activated macrophage-secreted Ear11. Mucosal Immunology. 14(1). 26–37. 11 indexed citations
2.
Wing, Mark. (2008). Monoclonal Antibody First Dose Cytokine Release Syndromes–Mechanisms and Prediction. Journal of Immunotoxicology. 5(1). 11–15. 46 indexed citations
3.
Nicholas, Richard, Sarah Stevens, Mark Wing, & Alastair Compston. (2003). Oligodendroglial-derived stress signals recruit microglia in vitro. Neuroreport. 14(7). 1001–1005. 9 indexed citations
4.
Nicholas, Richard, Sarah Stevens, Mark Wing, & D. A. S. Compston. (2002). Microglia-derived IGF-2 prevents TNFα induced death of mature oligodendrocytes in vitro. Journal of Neuroimmunology. 124(1-2). 36–44. 71 indexed citations
5.
Wing, Mark, et al.. (2002). In vitro preclinical lead optimisation technologies (PLOTs) in pharmaceutical development. Toxicology Letters. 127(1-3). 143–151. 15 indexed citations
6.
Nicholas, Richard, Mark Wing, & Alastair Compston. (2001). Nonactivated microglia promote oligodendrocyte precursor survival and maturation through the transcription factor NF‐κB. European Journal of Neuroscience. 13(5). 959–967. 90 indexed citations
7.
Isermann, Berend, Sara B. Hendrickson, Mark Zogg, et al.. (2001). Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. Journal of Clinical Investigation. 108(4). 537–546. 97 indexed citations
8.
Hall, Gillian L., John Girdlestone, D. A. S. Compston, & Mark Wing. (1999). Recall antigen presentation by γ-interferon-activated microglia results in T cell activation and propagation of the immune response. Journal of Neuroimmunology. 98(2). 105–111. 9 indexed citations
9.
Coles, Alasdair, Mark Wing, Francesca Coraddu, et al.. (1999). Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. The Lancet. 354(9191). 1691–1695. 335 indexed citations
10.
Hall, Gillian L., Mark Wing, D. A. S. Compston, & Neil Scolding. (1997). β-interferon regulates the immunomodulatory activity of neonatal rodent microglia. Journal of Neuroimmunology. 72(1). 11–19. 31 indexed citations
11.
Wing, Mark, T. Moreau, Judith Greenwood, et al.. (1996). Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.. Journal of Clinical Investigation. 98(12). 2819–2826. 185 indexed citations
12.
Isaacs, John D., Mark Wing, Judith Greenwood, et al.. (1996). A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clinical & Experimental Immunology. 106(3). 427–433. 48 indexed citations
13.
Moreau, Thibault, Alasdair Coles, Mark Wing, et al.. (1996). Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain. 119(1). 225–237. 204 indexed citations
14.
Wing, Mark. (1995). The molecular basis for a polyspecific antibody. Clinical & Experimental Immunology. 99(3). 313–315. 17 indexed citations
15.
Wing, Mark, et al.. (1993). Rapid isolation and biochemical characterization of rat C1 and C1q. Molecular Immunology. 30(5). 433–440. 17 indexed citations
16.
Montgomery, Anthony M.P., Mark Wing, & P. J. Lachmann. (1992). The targeting of T-helper cells and tumourcidal macrophages to a B-cell lymphoma using a PPD-monoclonal antibody heteroconjugate.. PubMed. 75(2). 217–23. 3 indexed citations
17.
Zajicek, John, Mark Wing, Neil Scolding, & D. A. S. Compston. (1992). INTERACTIONS BETWEEN OLIGODENDROCYTES AND MICROGLIA. Brain. 115(6). 1611–1631. 140 indexed citations
18.
Meri, Seppo, B. Paul Morgan, Mark Wing, et al.. (1990). Human protectin (CD59), an 18-20-kD homologous complement restriction factor, does not restrict perforin-mediated lysis.. The Journal of Experimental Medicine. 172(1). 367–370. 49 indexed citations
19.
Montgomery, Anthony M.P., Mark Wing, & P. J. Lachmann. (1990). A novel strategy for targeting CD4+ PPD-reactive T cells against tumour cells using PPD monoclonal antibody heteroconjugates. Clinical & Experimental Immunology. 82(2). 200–207. 4 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carol L. Vanderlugt Breakdown of academic impact, for papers by B. Cannella Breakdown of academic impact, for papers by Anthony Slavin Breakdown of academic impact, for papers by Virginia L. Calder Breakdown of academic impact, for papers by Dvora Teitelbaum Breakdown of academic impact, for papers by Sigrid R. Ruuls Breakdown of academic impact, for papers by Subramaniam Sriram Breakdown of academic impact, for papers by Nathan Karin Breakdown of academic impact, for papers by DeRen Huang Breakdown of academic impact, for papers by Masaaki Niino
Rankless by CCL
2026